HTR1E — 5-Hydroxytryptamine Receptor 1E

📖 Wiki Page

gene604 wordssynced 2026-04-02

HTR1E - 5-Hydroxytryptamine Receptor 1E

Introduction

Htr1E — 5 Hydroxytryptamine Receptor 1E is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@regional]
<table> [@hte]
<tr><th colspan="2" style="background:#4a90d9; color:white; text-align:center">HTR1E</th></tr> [@chromosome]
<tr><td>Gene Symbol</td><td>HTR1E</td></tr> [@regulation]
<tr><td>Full Name</td><td>5-Hydroxytryptamine Receptor 1E</td></tr> [@serotonergic]
<tr><td>Chromosomal Location</td><td>6q14.3</td></tr> [@htea]
<tr><td>NCBI Gene ID</td><td>3354</td></tr> [@serotonin]
<tr><td>UniProt ID</td><td>P28566</td></tr> [@receptors]
<tr><td>Protein Class</td><td>GPCR, 5-HT1 family</td></tr> [@basal]
<tr><td>Associated Diseases</td><td>AD, PD, Schizophrenia, Migraine</td></tr> [@altered]
</table> [@receptorsa]
</div> [@serotonina]

Overview

...

HTR1E - 5-Hydroxytryptamine Receptor 1E

Introduction

Overview

HTR1E encodes the 5-hydroxytryptamine receptor 1E (5-HT1E), a G protein-coupled receptor (GPCR) that mediates gi/o-coupled inhibitory serotonin signaling [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2140736/). This receptor is expressed in various brain regions including the frontal [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and basal ganglia, areas critically involved in cognition, memory, and motor control [2](https://pubmed.ncbi.nlm.nih.gov/8346269/). The 5-HT1E receptor represents an interesting pharmacological target due to its distinct regional distribution and coupling mechanisms [3](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725642/). [@neuroprotective]

Molecular Characteristics

Structure and Pharmacology

G protein coupling: Gi/o-coupled, inhibiting adenylyl cyclase
Signal transduction: Decreases intracellular cAMP levels
Ligand binding: High affinity for serotonin (5-HT) and various serotonergic drugs
Receptor distribution: Prefrontal cortex, hippocampus, basal ganglia, dorsal raphe nucleus

Gene Location and Regulation

The HTR1E gene is located on chromosome 6q14.3, a region linked to various neurological conditions [4](https://pubmed.ncbi.nlm.nih.gov/19058863/). Expression of 5-HT1E receptors is regulated by neural activity and may be altered in neurodegenerative states [5](https://pubmed.ncbi.nlm.nih.gov/11341774/). [@selective]

Role in Neurodegenerative Diseases

Alzheimer's Disease

The 5-HT1E receptor plays a modulatory role in cognitive processes that are compromised in Alzheimer's disease (AD). Serotonergic signaling through 5-HT1E receptors influences [amyloid-beta](/proteins/amyloid-beta) production and [tau](/proteins/tau) phosphorylation pathways [6](https://pubmed.ncbi.nlm.nih.gov/29335523/). Post-mortem studies have reported altered 5-HT1E receptor binding in the AD brain, particularly in the hippocampus and [entorhinal cortex](/brain-regions/entorhinal-cortex) [7](https://pubmed.ncbi.nlm.nih.gov/10482642/). These changes may contribute to memory deficits and cognitive decline observed in AD patients [8](https://pubmed.ncbi.nlm.nih.gov/22982676/). [@serotonergica]

Parkinson's Disease

In Parkinson's disease (PD), 5-HT1E receptors modulate dopaminergic transmission in the basal ganglia. Serotonergic drugs acting at 5-HT1E receptors may influence L-DOPA-induced dyskinesias and motor complications [9](https://pubmed.ncbi.nlm.nih.gov/20494142/). The receptor's expression on striatal [neurons](/entities/neurons) suggests a role in regulating motor function and movement disorders [10](https://pubmed.ncbi.nlm.nih.gov/24865511/).

Other Neurological Disorders

Schizophrenia: Altered 5-HT1E binding has been reported in prefrontal cortex [11](https://pubmed.ncbi.nlm.nih.gov/10746554/)
Migraine: 5-HT1E receptors are targeted by serotonergic migraine therapeutics [12](https://pubmed.ncbi.nlm.nih.gov/10634852/)
Depression: The receptor may contribute to mood regulation through serotonergic signaling pathways [13](https://pubmed.ncbi.nlm.nih.gov/11476338/)

Therapeutic Implications

Drug Development

The 5-HT1E receptor represents a potential target for neurodegenerative disease therapeutics. Selective 5-HT1E agonists may provide neuroprotective effects by modulating cAMP signaling and reducing excitotoxicity [14](https://pubmed.ncbi.nlm.nih.gov/22150525/). However, drug development has been limited by the lack of highly selective ligands [15](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308616/).

Combination Therapies

Given the complex neurotransmitter interactions in neurodegeneration, 5-HT1E-targeting drugs may be most effective in combination therapies that address multiple neurotransmitter systems. These approaches are particularly relevant for treating non-cognitive symptoms of dementia, including depression, anxiety, and behavioral disturbances [16](https://pubmed.ncbi.nlm.nih.gov/26517684/).

Research Directions

Development of selective 5-HT1E agonists/antagonists for clinical use
Understanding receptor polymorphisms and their impact on disease progression
Investigating 5-HT1E interactions with other neurotransmitter systems
PET ligand development for in vivo receptor imaging

Background

The study of Htr1E — 5 Hydroxytryptamine Receptor 1E has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

HTR1E — 5-Hydroxytryptamine Receptor 1E

HTR1E - 5-Hydroxytryptamine Receptor 1E

Introduction

Overview

HTR1E - 5-Hydroxytryptamine Receptor 1E

Introduction

Overview

Molecular Characteristics

Structure and Pharmacology

Gene Location and Regulation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurological Disorders

Therapeutic Implications

Drug Development

Combination Therapies

Research Directions

Background

See Also